As Alzheimer’s meeting begins, researchers seize on signs of progress

There is a huge market opportunity waiting for any drug that can halt or at least slow down its progression.

A lot of attention was also given to the search for new, reliable biomarkers of Alzheimer’s disease. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals.

These diseases cause a range of debilitating symptoms, including memory loss, difficulty with language, visual hallucinations or problems with movement, but they all share the same hallmark – the death of brain cells.

It’s not easy to diagnose Alzheimer’s disease even after it develops. But, there are other brain changes that can also contribute to dementia, the study authors noted. Infarcts in brain are reportedly associated with stroke and Lewy bodies are associated with Parkinson’s Disease.

– Pipeline products coverage based on various stages of development from NDA filings to discovery.

Scientists will present their results from the drug’s clinical trial next week in Washington.

Most people probably know someone who is affected by it. Well, fortunately, a new drug that will be able to prevent Alzheimer’s disease is expected to be announced sometime this week. The research may prove beneficial when it comes to explaining as to why blacks in the United States are twice more likely to develop Alzheimer’s disease than American of European descent.

Alzheimer’s researcher Professor Christian Holscher, of Lancaster University, said: “I am confident some of the new approaches being taken will genuinely improve the condition and I am pretty sure we will find a cure for this bad disease in my lifetime”.

Alzheimer’s disease affects some 5 million Americans, and over the next 30 years that number could triple, says Dr. Reisa Sperling, a neurologist at Boston’s Brigham and Women’s Hospital. “Pending regulatory approval, we plan to begin clinical testing in people with Alzheimer’s in early 2016”. Three types of monoclonal antibodies from their laboratory were used, each of which binds to amyloid and tau and also reverses Alzheimer’s-like damage to brain tissue in animals.

On Wednesday, researchers will present data on mild Alzheimer’s patients from those extension studies.

Using computer modeling techniques, Taylor and colleagues identified an abnormal shape that enables a protein to misfold and become toxic. This could allow natural clearing mechanisms to remove existing protein aggregates and improve cognitive function.

About the Alzheimer’s AssociationThe Alzheimer’s Association is the leading voluntary health organization in Alzheimer’s care, support and research.

The researchers have said that African-Americans are more at risk to suffer from different types of brain changes. Visit alz.org or call 800.272.3900.